BackMankind Pharma Limited Overview

Mankind Pharma Limited Receivables

Track Mankind Pharma Limited's receivables ($22B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$21.82B
↑ 14.59% YoYΔ $2.78B vs prior year quarter

Peer trimmed avg / median

Loading

Mankind Pharma Limited Receivables History

Loading

Mankind Pharma Limited vs. peers: Receivables Comparison

Loading

Mankind Pharma Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Mankind Pharma Limited (MANKIND.BO) FAQ

Mankind Pharma Limited posts a receivables of $22B as of September 2026. That compares with $19B in the prior-year period — up 14.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Mankind Pharma Limited's receivables was $19B. The latest reading is $22B — a 14.6% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Mankind Pharma Limited's financial statement story. At $22B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MANKIND.BO's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Mankind Pharma Limited's other metric pages and overview cover the third.

Questions & Answers